Enhanced plasma persistence of therapeutic enzymes by coupling to soluble dextran.
Conjugation of carboxypeptidase G and arginase, two enzymes of therapeutic interest, to a soluble dextran significantly enhanced plasma persistence in normal and tumour-bearing mice. A prolonged decrease in arginine concentrations in plasma of tumour-bearing mice was demonstrated by using the dextran-linked arginase. Gel filtration of dextran-enzyme conjugate showed that enzyme activity co-chromatographed as a single peak with carbohydrate, and enzyme was shown to be covalently linked to the dextran.
D000818:Animals; D001119:Arginase / Q000097:blood / Q000627:therapeutic use*; D001682:Biological Availability; D002268:Carboxypeptidases / Q000097:blood / Q000627:therapeutic use*; D003911:Dextrans; D005260:Female; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010592:Pharmaceutic Aids
D003911:Dextrans; D010592:Pharmaceutic Aids; D002268:Carboxypeptidases; D001119:Arginase